论文部分内容阅读
目的:检测结直肠癌患者外周血中细胞角蛋白20(CK20)mRNA的表达,并探讨其临床价值。方法:应用实时荧光定量逆转录聚合酶链反应,检测59例结直肠癌患者、12例原发性肝癌患者和26例对照者外周血中CK20 mRNA的表达。结果:对照者及原发性肝癌患者外周血中CK20 mRNA均为阴性表达。结直肠癌患者外周血中CK20 mRNA阳性表达率为59.3%。结直肠癌患者外周血中CK20 mRNA的阳性表达率在不同肿瘤病理分化程度中差异无显著性,而在不同Dukes分期和有无淋巴结转移及远处转移患者间差异有显著性(P<0.05)。结论:检测结直肠癌患者外周血中CK20 mRNA的表达可作为预测肿瘤微转移的评估指标,可监测患者病情变化,识别高危人群,并有助于结直肠癌微转移的判断及鉴别原发性肝细胞肝癌和结直肠癌肝转移。
Objective: To detect the expression of cytokeratin 20 (CK20) mRNA in peripheral blood of patients with colorectal cancer and to explore its clinical value. Methods: The expression of CK20 mRNA in peripheral blood of 59 patients with colorectal cancer, 12 patients with primary liver cancer and 26 controls were detected by real-time fluorescence quantitative polymerase chain reaction. Results: CK20 mRNA in peripheral blood of control and primary liver cancer patients were negative. The positive rate of CK20 mRNA in peripheral blood of patients with colorectal cancer was 59.3%. The positive expression rate of CK20 mRNA in peripheral blood of patients with colorectal cancer had no significant difference in the pathological differentiation between different tumor types, but there was significant difference between different Dukes stage and lymph node metastasis and distant metastasis (P <0.05) . Conclusion: Detecting the expression of CK20 mRNA in peripheral blood of patients with colorectal cancer can be used as an index to predict the micrometastasis of the tumor. It can monitor the patient’s condition, identify the high risk group, and help to judge the micrometastasis of colorectal cancer and identify the primary Hepatocellular carcinoma and colorectal liver metastases.